Guillaume Leroy built his career at the forefront of global public health innovation. At Sanofi Pasteur, he led multicultural teams across Latin America, Africa and at global headquarters, deploying large-scale public health programs in emerging markets. He played a key role in developing the world's first dengue vaccine, combining scientific vision with operational execution at scale. He went on to lead Sanofi France, first as CEO, then as President. In 2021, he founded GLS Advisory to advise biotech, pharma and MedTech companies, and took the helm of EdJen Biotech, dedicated to first-in-class peptide vaccine development.

Running a Scientific Advisory Board is critical for any life sciences company and painfully expensive. An early-stage startup spends around €50K per year on its SAB; by Series A, that figure doubles. Board members are hard to gather : they're senior, in-demand, and booked months ahead. When they do meet, preparation makes or breaks the session. Yet most companies still walk in with undercooked analyses, wasting the one moment their top experts are in the room.

The  Scientific Advisory Board (SAB) Kin analyzes your R&D data ahead of each session: literature review (including grey literature), methodology assessment against domain standards, and actionable recommendations. It delivers a structured PDF report in 1 to 2 hours. Your experts arrive with a rigorous analysis already done. They focus on what only they can do: challenge, orient, decide. Need a quick answer between sessions? The Kin delivers without waiting for the next board meeting.

• Pre-session SAB preparation : You have a board meeting in two weeks and your R&D team just delivered new results. The Kin analyzes your data against current literature, evaluates your methodology and produces a structured briefing document. Your SAB members receive a rigorous analysis before they walk in, every minute of the session goes to high-value discussion.

• Urgent scientific decision between sessions : A competitor publishes unexpected results. A clinical endpoint needs reassessing. You can't wait three months for the next SAB meeting. The Kin delivers a focused analysis in under two hours, giving you the scientific grounding to move forward with confidence.

• Methodology challenge for R&D teams : Your internal team has designed a protocol but needs an independent critical eye before committing resources. The Kin evaluates your methodological choices against domain standards, flags potential weaknesses and suggests alternatives before your SAB members have to do it in real time.

• Scientific due diligence for investors : You're evaluating a biotech's pipeline and need to assess the scientific rigor behind their claims. The Kin reviews their published data, cross-references with current literature and delivers a structured assessment giving you an expert-grade second opinion without engaging a full advisory team.

Today, most SAB sessions start with 30 minutes of context-setting and end with the feeling that the real conversation barely began. With the SAB Kin, preparation time drops from weeks to hours. Experts arrive with a complete, structured analysis already in hand. Every minute of board time goes to what only humans can do: challenge assumptions, weigh trade-offs, and make strategic calls.

For companies, the shift is structural. You no longer need to choose between convening the full board and making decisions in the dark. The Kin gives you expert-grade scientific analysis on demand, on your timeline, not your advisors' calendars. The result: faster decisions, sharper governance, and a SAB that finally delivers its full value.